Publication:
Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes

dc.contributor.authorChompoonuch Sawaengsaken_US
dc.contributor.authorYasuko Morien_US
dc.contributor.authorKoichi Yamanishien_US
dc.contributor.authorPotjanee Srimanoteen_US
dc.contributor.authorWanpen Chaicumpaen_US
dc.contributor.authorAmpol Mitrevejen_US
dc.contributor.authorNuttanan Sinchaipaniden_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNational Institute of Biomedical Innovationen_US
dc.contributor.otherKobe University School of Medicineen_US
dc.contributor.otherThammasat Universityen_US
dc.date.accessioned2018-11-09T03:09:36Z
dc.date.available2018-11-09T03:09:36Z
dc.date.issued2014-10-01en_US
dc.description.abstractAn egg-free and broadly effective influenza vaccine that can be produced rapidly, adequately and cost-effectively is needed. In this study, chitosan-associated DNAs prepared at various nitrogen/phosphate charge (N/P) ratios were studied for their physicochemical properties, stability, cytotoxicity, and protein expression ability. The chitosan-DNA complexes (chitoplexes) of the N/P ratio 2 had the required characteristics including optimal size range, positive surface charge, high DNA association efficiency, tolerability to DNase digestion and mammalian cell viability compatibility. The N/P ratio 2-chitoplexes revealed the highest green fluorescent protein and luciferase expressions in the transfected mammalian cell cultures and in the mouse lungs. Mice immunized intranasally with the N/P ratio 2-chitoplex vaccines carrying DNAs coding for conserved proteins of influenza virus, i.e., ion channel protein (M2) and/or nucleoprotein (NP), had both mucosal and systemic humoral as well as cell mediated immune responses to the in vivo expressed antigens which conferred protection in mice against the lethal challenges not only with the homologous influenza virus subtype (H1N1), but also the heterologous subtype (H3N2). The chitoplexes should be considered as influenza vaccine candidates especially during the period of high vaccine demand. They are suitable for developing areas of the world where conventional vaccine production capacity is lacking. © 2014 Elsevier B.V.en_US
dc.identifier.citationInternational Journal of Pharmaceutics. Vol.473, No.1-2 (2014), 113-125en_US
dc.identifier.doi10.1016/j.ijpharm.2014.07.005en_US
dc.identifier.issn18733476en_US
dc.identifier.issn03785173en_US
dc.identifier.other2-s2.0-84904332164en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/34897
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84904332164&origin=inwarden_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleIntranasal chitosan-DNA vaccines that protect across influenza virus subtypesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84904332164&origin=inwarden_US

Files

Collections